GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Interesting article indeed but I am not sure if it is a positive or a negative for GTCB. Are you inferring that ATryn has the potential to act as an anti-inflammatory agent as well as an anti-coagulation agent using two different pathways, or are you saying that the promise of ATryn in sepsis may not be as remarkable as once thought because it will have no effect on the inflammatory process? In other words, is the anti-inflammatory potential of ATryn in sepsis established or is it merely a conjecture?<

The anti-inflammatory action of antithrombin is well-established and is the reason ATryn may one day be tested in various inflammatory conditions (e.g. see #msg-12198247).

For DIC/sepsis in particular, the abstract in #596 is neither strongly positive nor strongly negative; the finding that the two pathways do not overlap can perhaps be construed as a mild positive in that it may make it easier to for ATryn to have predictable PK/PD characteristics. Regards, Dew